Results 11 to 20 of about 57,965 (293)
Safety of proton pump inhibitors [PDF]
Alimentary Pharmacology & Therapeutics, 2000 Helge L. Waldum +2 more
openalex +4 more sources
Proton pump inhibitors and gastroenteritis [PDF]
European Journal of Epidemiology, 2016 An association between proton pump inhibitor (PPI) therapy and bacterial gastroenteritis has been suggested as well as contradicted. The aim of this study was to examine the association between the use of PPIs and occurrence of bacterial gastroenteritis in the prospective Rotterdam Study.
Annelies Verbon +4 more
openaire +3 more sources
World Chinese Journal of Digestology, 2013 Proton pump inhibitors (PPIs), omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole, and dexlansoprazole bind irreversibly to the H+, K+- ATPase (the “proton pump”) inhibiting its activity and decreasing gastric acid production.
Nghia H. Pham, Brian A. Baldo
openaire +4 more sources
BMC Geriatrics, 2022 Background Proton pump inhibitors, benzodiazepines, and antipsychotics are considered potentially inappropriate medications in older adults according to the American Geriatric Society Beers Criteria, and deprescribing algorithms have been developed to ...
Jennifer M. Toth +3 more
doaj +1 more source
Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics
Frontiers in Pharmacology, 2020 BackgroundDue to their efficacy and tolerability, utilization of proton pump inhibitors (PPI) has significantly increased worldwide. Parallel to the clinical benefits, potential long-term side effects have been observed, which, along with increasing ...
Mária Matuz +7 more
doaj +1 more source
Dermatology Practical & Conceptual, 2015 Background: Sweet’s syndrome, also referred to as acute febrile neutrophilic dermatosis, can either occur as an idiopathic disorder or associated with another condition, including cancer, or induced by exposure to a drug.
Philip R. Cohen
doaj +1 more source
Proton Pump Inhibitors and Gastritis
Journal of Clinical Biochemistry and Nutrition, 2008 Proton pump inhibitors (PPIs) are novel compounds that strongly inhibit the H(+)/K(+)-ATPase in the gastric parietal cells to cause profound suppression of acid secretion. Acid-generating ATPase, also known as vacuolar-type ATPase, is located in the lysozomes of leukocytes and osteoclasts and its activity is also reportedly influenced by treatment with
Toshifumi Hibi +2 more
openaire +4 more sources
Proton Pump Inhibitors and Clopidogrel [PDF]
Cardiovascular Therapeutics, 2010 Proton pump inhibitors are often prescribed for patients on clopidogrel to prevent gastrointestinal bleeding complications. Recent data suggest higher rates of adverse cardiovascular events in patients on proton pump inhibitors and clopidogrel, in comparison to patients on clopidogrel only.
Ron Waksman, Michael A. Gaglia
openaire +2 more sources
Journal of Indian Academy of Oral Medicine and Radiology, 2020 Background: Oral leukoplakia is a white patch or plaque that cannot be characterized clinically or pathologically as any other disease and is not associated with any physical or chemical causative agent except the use of tobacco.
Nivethitha Nagarajan, S Jayachandran
doaj +1 more source
Proton Pump Inhibitor-Related Gastric Mucosal Changes
Gut and Liver, 2021 Proton pump inhibitors (PPIs) are used worldwide to treat of acid-related disorders such as peptic ulcer and gastroesophageal reflux disease and to prevent gastroduodenal injuries due to nonsteroidal anti-inflammatory drugs.
Gwang Ha Kim
doaj +1 more source